M&A Deal Summary |
|
|---|---|
| Date | 2015-12-17 |
| Target | Acerta Pharma BV |
| Sector | Life Science |
| Buyer(s) | AstraZeneca |
| Deal Type | Add-on Acquisition |
| Deal Value | 4.0B USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Employees | 83,100 |
| Revenue | 54.1B USD (2024) |
AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 12 of 23 |
| Sector: Life Science M&A | 10 of 21 |
| Type: Add-on Acquisition M&A Deals | 9 of 17 |
| Country: Netherlands M&A | 1 of 1 |
| Year: 2015 M&A | 3 of 3 |
| Size (of disclosed) | 3 of 19 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-12-16 |
Takeda Pharmaceutical Company - Core Respiratory Business
Japan Takeda Pharmaceutical Company Limited's core respiratory business includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD). |
Buy | $575M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-08-24 |
AstraZeneca - Small Molecule Anti-Infective Business
London, United Kingdom AstraZeneca - Small Molecule Anti-Infective Business includes the commercialization and development rights to the newly approved EU drug Zavicefta™ (ceftazidime-avibactam), the marketed agents Merrem™/Meronem™ (meropenem) and Zinforo™ (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL. |
Sell | $550M |
